Development and characterization of palmitoyl-modified arginine containing curcumin-loaded niosomal vesicles for improved antioxidant and anticancer activities
Khadija Rehman, Tasmina Kanwal, Ali Asgher Shuja, Salim Saifullah, Shabana Usman Simjee, Muhammad Raza Shah
{"title":"Development and characterization of palmitoyl-modified arginine containing curcumin-loaded niosomal vesicles for improved antioxidant and anticancer activities","authors":"Khadija Rehman, Tasmina Kanwal, Ali Asgher Shuja, Salim Saifullah, Shabana Usman Simjee, Muhammad Raza Shah","doi":"10.1007/s00396-024-05299-y","DOIUrl":null,"url":null,"abstract":"<div><p>The objective of this study was to enhance the anticancer potential of curcumin (CR)-loaded niosomal formulation against human myeloid leukemia cell lines and its antioxidant activity by the incorporation of amphiphilic palmitoyl-modified arginine (PL-ARG) serving as a positively charged amphiphile. PL-ARG was synthesized by using palmitoyl chloride (PL) and <span>l</span>-arginine (ARG) followed by characterization through ESI–MS, <sup>1</sup>H-NMR, and FT-IR. The proportion of niosomal constituents including Tween 80/20 and cholesterol was optimized using experimental design to achieve small size vesicle with enhanced encapsulation of CR, and the optimized proportion was then used for the development of niosomal formulation functionalized with synthesized PL-ARG (PL-ARG-CR-NSMs). For the comparison, non-functionalized CR-loaded niosomes (CR-NSMs) were also prepared. The developed niosomal vesicles were characterized for encapsulation efficiency, size, PDI, zeta potential and surface morphology, and in vitro drug release. CR was encapsulated in niosomes with entrapment efficiency of 78.94 ± 5.16% (PL-ARG-CR-NSMs) and 65.82 ± 3.52% (CR-NSM) and provided a sustained drug release profile. Interestingly, when compared to CR-NSMs, the PL-ARG-CR-NSMs demonstrated enhanced growth inhibition of human myeloid leukemia cell lines supporting the antitumor efficacy of CR delivered from PL-ARG-CR-NSMs against human myeloid leukemia cell lines as well as the feasibility of arginine modified niosomes as a sustainable cancer treatment approach.</p><h3>Graphical Abstract</h3><div><figure><div><div><picture><source><img></source></picture></div></div></figure></div></div>","PeriodicalId":520,"journal":{"name":"Colloid and Polymer Science","volume":null,"pages":null},"PeriodicalIF":2.2000,"publicationDate":"2024-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Colloid and Polymer Science","FirstCategoryId":"92","ListUrlMain":"https://link.springer.com/article/10.1007/s00396-024-05299-y","RegionNum":4,"RegionCategory":"化学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CHEMISTRY, PHYSICAL","Score":null,"Total":0}
引用次数: 0
Abstract
The objective of this study was to enhance the anticancer potential of curcumin (CR)-loaded niosomal formulation against human myeloid leukemia cell lines and its antioxidant activity by the incorporation of amphiphilic palmitoyl-modified arginine (PL-ARG) serving as a positively charged amphiphile. PL-ARG was synthesized by using palmitoyl chloride (PL) and l-arginine (ARG) followed by characterization through ESI–MS, 1H-NMR, and FT-IR. The proportion of niosomal constituents including Tween 80/20 and cholesterol was optimized using experimental design to achieve small size vesicle with enhanced encapsulation of CR, and the optimized proportion was then used for the development of niosomal formulation functionalized with synthesized PL-ARG (PL-ARG-CR-NSMs). For the comparison, non-functionalized CR-loaded niosomes (CR-NSMs) were also prepared. The developed niosomal vesicles were characterized for encapsulation efficiency, size, PDI, zeta potential and surface morphology, and in vitro drug release. CR was encapsulated in niosomes with entrapment efficiency of 78.94 ± 5.16% (PL-ARG-CR-NSMs) and 65.82 ± 3.52% (CR-NSM) and provided a sustained drug release profile. Interestingly, when compared to CR-NSMs, the PL-ARG-CR-NSMs demonstrated enhanced growth inhibition of human myeloid leukemia cell lines supporting the antitumor efficacy of CR delivered from PL-ARG-CR-NSMs against human myeloid leukemia cell lines as well as the feasibility of arginine modified niosomes as a sustainable cancer treatment approach.
期刊介绍:
Colloid and Polymer Science - a leading international journal of longstanding tradition - is devoted to colloid and polymer science and its interdisciplinary interactions. As such, it responds to a demand which has lost none of its actuality as revealed in the trends of contemporary materials science.